What Awaits ACUR & Other Drug Stocks This Earnings Season?
Zacks Investment Research | Jul 28, 2016 09:43PM ET
Getting into the thick of the Q2 earnings season, we have seen releases from 208 S&P 500 members, accounting for 50.5% of the index’s total market capitalization, as of Jul 27. As per our Earnings Trend report, earnings for these companies have declined 4.7% on a year-over-year basis on 0.4% higher revenues. In spite of bleak year-over-year comparisons, a whopping 73.1% were able to surpass earnings estimates, while 51.9% beat on revenues.
Although Q2 is still on track to be the fifth quarter in a row to record negative earnings growth, the rate of growth is showing modest improvement from last quarter. Going forward, even though estimates for the third quarter are still moving south, the magnitude of the fall has lessened down.
Medical is one of the six sectors that are projected to record positive earnings growth this quarter. Earnings in the sector are expected to increase 2.3% on revenue growth of 7.7%. Within the S&P 500 index, 36.5% of the companies in the Medical sector have reported results so far, putting up an average earnings decline of 0.3% on 12.6% higher revenues and resulting in a blended beat of 78.9%. Bigwigs like Johnson & Johnson (NYSE:JNJ) , Novartis AG (NYSE:NVS) and Abbott Laboratories (NYSE:ABT) were able to beat expectations comfortably. In the biotech space, Gilead Sciences (NASDAQ:GILD) missed on revenues in spite of an earnings beat, while Biogen (NASDAQ:BIIB) topped bottom-line estimates.
Let’s see what’s in store for a few companies that are scheduled to report results early next week.
Illinois-based Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) is scheduled to report second-quarter 2016 results on Aug 1. The specialty pharmaceutical company is engaged in the development and commercialization of technologies and products for addressing medication abuse and misuse. The company uses its three proprietary platform technologies – Aversion, Limitx and Impede – to develop multiple products. Acura has a dismal track record so far, having missed estimates in the past two quarters. For this quarter, the company has a Zacks Rank #3 (Hold) and an Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.